Albert Bourla - Dec 15, 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role
Chairman & CEO, Director
Signature
Susan E. Grant, by power of atty., for Albert Bourla
Stock symbol
PFE
Transactions as of
Dec 15, 2022
Transactions value $
$6,059,116
Form type
4
Date filed
12/16/2022, 05:14 PM
Previous filing
Dec 1, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $4.02M +133K +70.25% $30.17 323K Dec 16, 2022 Direct F1
transaction PFE Common Stock Options Exercise $2.04M +89.2K +27.63% $22.89 412K Dec 16, 2022 Direct F2
holding PFE Common Stock 4.15K Dec 15, 2022 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Phantom Stock Units SSP Award $536 +10 +0.01% $53.61 96.4K Dec 15, 2022 Common Stock 10 Direct F3, F4
transaction PFE Stock Appreciation Rights Options Exercise $0 -285K -100% $0.00* 0 Dec 16, 2022 Common Stock 285K $30.17 Direct
transaction PFE Stock Appreciation Rights Options Exercise $0 -146K -100% $0.00* 0 Dec 16, 2022 Common Stock 146K $22.89 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
F2 Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.
F3 Each unit represents one phantom share of common stock.
F4 These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.